Ignite Creation Date:
2024-05-06 @ 11:01 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03413410
Status:
UNKNOWN
Last Update Posted:
2019-07-19
First Post:
2018-01-11
Brief Title:
A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome
Sponsor:
Yun Dai Chen
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome
Status:
UNKNOWN
Status Verified Date:
2019-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to test the feasibility and tolerability of the metoprolol optimal dosing pathway by observing the percentage of patients achieving target dose followed the pathway on ACS patients during hospitalization
Detailed Description:
Acute coronary syndromeACS is one of the main manifestations of cardiovascular disease and one of the main causes for hospitalization in adults
Previous studies showed that β-receptor blockers can reduce ACS patients cardiovascular risk in both acute phase and secondary prevention We summarized the metoprolol optimal dosing pathway based on Chinese and foreign guidelines as well as Chinese clinical practice
Primary endpoint is the percentage of patients achieving target dose at time of discharge
Secondary endpoints are the mean HR BP at discharge and during the follow up period of the Patients who have achieved target dose at discharge
Previous studies showed that β-receptor blockers can reduce ACS patients cardiovascular risk in both acute phase and secondary prevention We summarized the metoprolol optimal dosing pathway based on Chinese and foreign guidelines as well as Chinese clinical practice
Primary endpoint is the percentage of patients achieving target dose at time of discharge
Secondary endpoints are the mean HR BP at discharge and during the follow up period of the Patients who have achieved target dose at discharge
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None